Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 42
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3
Ioannis‐Alexios Koumprentziotis, Charalampos Theocharopoulos, Dimitra Foteinou, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 54-54
Open Access | Times Cited: 14
Epigenetic regulation of tumor immunity
Lizhi Pang, Fei Zhou, Yang Liu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 12
Open Access | Times Cited: 8
STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop
Zhaozhou Ren, Zhijie Xu, Xiyue Chang, et al.
Pharmacological Research (2024) Vol. 204, pp. 107218-107218
Open Access | Times Cited: 7
Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent
Víctor Albarrán, Patrícia Guerrero, Coral García de Quevedo, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 7
A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis
Hefei Ren, Chang Liu, Cheng Zhang, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 15
Role of Exosomes in Cancer and Aptamer-Modified Exosomes as a Promising Platform for Cancer Targeted Therapy
Yating Wu, Yue Cao, Li Chen, et al.
Biological Procedures Online (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 5
Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance
Aurélie H. Benfield, Felicitas Vernen, Reuben S. E. Young, et al.
Pharmacological Research (2024) Vol. 207, pp. 107298-107298
Open Access | Times Cited: 5
Comprehensive Breslow thickness (BT)-based analysis to identify biological mechanisms associated with melanoma pathogenesis
Yuanjie Liu, Qing Liu, Jiaqi Li, et al.
International Immunopharmacology (2025) Vol. 147, pp. 114065-114065
Closed Access
Inflammasome activation in melanoma progression: the latest update concerning pathological role and therapeutic value
Nakaraj Pluetrattanabha, Thanyaporn Direksunthorn, Irfan Ahmad, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors
Yao Liang, Osamu Maeda, Kazuki Nishida, et al.
Cancer Science (2025)
Open Access
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
M.K. Zielińska, Magdalena Ciążyńska, Dorota Sulejczak, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 269-269
Open Access
Inhibiting melanoma tumor growth: the role of oxidative stress-associated LINC02132 and COPDA1 long non-coding RNAs
Jingwen Xu, Mingzhu Jin, Zhenzhen Mu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO‐Mediated Tryptophan Metabolism
Yawen Zhou, Qian Tao, Chu‐Bin Luo, et al.
Cancer Science (2025)
Open Access
C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors
Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, et al.
Melanoma Research (2025)
Closed Access
An Anionic Cathelicidin Exerts Antimelanoma Effects in Mice by Promoting Pyroptosis
Qian Chen, Guizhu Feng, Yan Shen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Case Report: Durable remission after abscopal effect following transcatheter hepatic arterial embolization in a patient with mucosal melanoma refractory to immunotherapy
L. Claus, Hannah E. Kostan, Marshall E. Hicks, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Lidy Vannessa Mejía-Guarnizo, Paula Stefany Monroy-Camacho, Andrés David Turizo-Smith, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients
Jingjing Zhang, Lei Wang, Shasha Zhang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells
Jie Zhang, Longsheng Wang, Hongjie Guo, et al.
Pharmacological Research (2024) Vol. 209, pp. 107458-107458
Open Access | Times Cited: 4
Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity
Dianying Zhang, Jingjing Zhao, Yujing Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Katerina Aravantinou, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104635-104635
Open Access
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation
Eleni Palli, Matthieu D. Lavigne, Panagiotis Verginis, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review
Elena Giovannini, Maria Paola Bonasoni, Michele D’Aleo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10919-10919
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top